Valuation: ZIM Laboratories Limited

Market Cap 7.44B 77.88M 67.1M 63.54M 57.59M 108M 109M 755M 290M 3.79B 292M 286M 11.96B P/E 2025
32.1x
P/E 2026 50.3x
Enterprise Value 8.3B 86.92M 74.89M 70.91M 64.27M 121M 121M 842M 324M 4.22B 326M 319M 13.35B EV / Sales 2025
1.34x
EV / Sales 2026 1.09x
Free-Float
28.77%
Yield 2025 *
-
Yield 2026 -
1 day+1.68%
1 week+10.67%
Current month+12.37%
1 month+27.19%
3 months+23.02%
6 months+108.35%
Current year+93.28%
1 week 126.25
Extreme 126.25
144.85
1 month 108.45
Extreme 108.45
144.85
Current year 59.72
Extreme 59.72
144.85
1 year 59.72
Extreme 59.72
144.85
3 years 59.72
Extreme 59.72
144.85
5 years 36.37
Extreme 36.366666
151.75
10 years 14
Extreme 14
151.75
Manager TitleAgeSince
Chief Executive Officer - 01/01/2002
Director of Finance/CFO - 01/04/2019
Director of Finance/CFO - 01/01/1991
Director TitleAgeSince
Chairman - 01/01/1990
Director/Board Member - 01/01/1991
Director/Board Member - 01/01/2013
Change 5-day change 1-year change 3-year change Capi.($)
+1.68%+10.67%+82.97%+17.60% 77.88M
-1.13%-3.11%+13.82%+60.17% 46.21B
-0.62%-3.96%+32.92%+106.77% 38.78B
+0.12%-0.08%+7.12%+73.98% 11.68B
-0.53%-1.37%-13.25%+11.19% 11.55B
-0.38%-2.26%+18.18%+142.99% 9.14B
+0.16%-1.49%+23.47%+35.50% 7.3B
+0.17%-0.74%+13.44%+180.68% 7.15B
+0.75%-3.35%+34.11%-19.22% 7.1B
-3.13%-4.30%-44.88%+12.88% 4.97B
Average -0.30%-1.27%+16.79%+62.26% 14.39B
Weighted average by Cap. -0.64%-3.26%+16.01%+74.33%

Financials

2025 2026
Net sales 3.79B 39.69M 34.19M 32.38M 29.35M 55.05M 55.33M 385M 148M 1.93B 149M 146M 6.09B 3.74B 39.19M 33.77M 31.97M 28.98M 54.37M 54.64M 380M 146M 1.9B 147M 144M 6.02B
Net income 122M 1.27M 1.1M 1.04M 942K 1.77M 1.78M 12.34M 4.74M 61.89M 4.78M 4.68M 196M 58.38M 611K 527K 499K 452K 848K 852K 5.92M 2.28M 29.7M 2.3M 2.24M 93.85M
Net Debt 1.16B 12.12M 10.44M 9.89M 8.96M 16.81M 16.9M 117M 45.15M 589M 45.51M 44.51M 1.86B 863M 9.03M 7.78M 7.37M 6.68M 12.53M 12.6M 87.53M 33.66M 439M 33.93M 33.18M 1.39B
Logo ZIM Laboratories Limited
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
Employees
632
Date Price Change Volume
11/09/26 ₹138.95 +1.68% 9,466
10/09/26 ₹136.65 +2.78% 17,475
09/09/26 ₹132.95 +2.94% 7,870
08/09/26 ₹129.15 0.00% 1,834
07/09/26 ₹129.15 +2.87% 7,712
  1. Stock Market
  2. Stocks
  3. ZIMLAB Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!